Interleukin-18 as a Therapeutic Target in Acute Myocardial Infarction and Heart Failure
Abstract Interleukin 18 (IL-18) is a proinflammatory cytokine in the IL-1 family that has been implicated in a number of disease states. In animal models of acute myocardial infarction (AMI), pressure overload, and LPS-induced dysfunction, IL-18 regulates cardiomyocyte hypertrophy and induces cardiac contractile dysfunction and extracellular matrix remodeling. In patients, high IL-18 levels correlate with increased risk of developing cardiovascular disease (CVD) and with a worse prognosis in patients with established CVD. Two strategies have been used to counter the effects of IL-18:IL-18 binding protein (IL-18BP), a naturally occurring protein, and a neutralizing IL-18 antibody. Recombinant human IL-18BP (r-hIL-18BP) has been investigated in animal studies and in phase I/II clinical trials for psoriasis and rheumatoid arthritis. A phase II clinical trial using a humanized monoclonal IL-18 antibody for type 2 diabetes is ongoing. Here we review the literature regarding the role of IL-18 in AMI and heart failure and the evidence and challenges of using IL-18BP and blocking IL-18 antibodies as a therapeutic strategy in patients with heart disease..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2014 |
---|---|
Erschienen: |
2014 |
Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
---|---|
Enthalten in: |
Molecular medicine - 20(2014), 1 vom: Jan., Seite 221-229 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
O’Brien, Laura C. [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
BKL: |
---|
doi: |
10.2119/molmed.2014.00034 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR008067945 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR008067945 | ||
003 | DE-627 | ||
005 | 20230519172807.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201005s2014 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2119/molmed.2014.00034 |2 doi | |
035 | |a (DE-627)SPR008067945 | ||
035 | |a (SPR)molmed.2014.00034-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.00 |2 bkl | ||
100 | 1 | |a O’Brien, Laura C. |e verfasserin |4 aut | |
245 | 1 | 0 | |a Interleukin-18 as a Therapeutic Target in Acute Myocardial Infarction and Heart Failure |
264 | 1 | |c 2014 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Interleukin 18 (IL-18) is a proinflammatory cytokine in the IL-1 family that has been implicated in a number of disease states. In animal models of acute myocardial infarction (AMI), pressure overload, and LPS-induced dysfunction, IL-18 regulates cardiomyocyte hypertrophy and induces cardiac contractile dysfunction and extracellular matrix remodeling. In patients, high IL-18 levels correlate with increased risk of developing cardiovascular disease (CVD) and with a worse prognosis in patients with established CVD. Two strategies have been used to counter the effects of IL-18:IL-18 binding protein (IL-18BP), a naturally occurring protein, and a neutralizing IL-18 antibody. Recombinant human IL-18BP (r-hIL-18BP) has been investigated in animal studies and in phase I/II clinical trials for psoriasis and rheumatoid arthritis. A phase II clinical trial using a humanized monoclonal IL-18 antibody for type 2 diabetes is ongoing. Here we review the literature regarding the role of IL-18 in AMI and heart failure and the evidence and challenges of using IL-18BP and blocking IL-18 antibodies as a therapeutic strategy in patients with heart disease. | ||
700 | 1 | |a Mezzaroma, Eleonora |e verfasserin |4 aut | |
700 | 1 | |a Van Tassell, Benjamin W. |e verfasserin |4 aut | |
700 | 1 | |a Marchetti, Carlo |e verfasserin |4 aut | |
700 | 1 | |a Carbone, Salvatore |e verfasserin |4 aut | |
700 | 1 | |a Abbate, Antonio |e verfasserin |4 aut | |
700 | 1 | |a Toldo, Stefano |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Molecular medicine |d [London] : BioMed Central, 1994 |g 20(2014), 1 vom: Jan., Seite 221-229 |w (DE-627)SPR008052611 |w (DE-600)1475577-4 |x 1528-3658 |7 nnns |
773 | 1 | 8 | |g volume:20 |g year:2014 |g number:1 |g month:01 |g pages:221-229 |
856 | 4 | 0 | |u https://dx.doi.org/10.2119/molmed.2014.00034 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 44.00 |q ASE |
951 | |a AR | ||
952 | |d 20 |j 2014 |e 1 |c 01 |h 221-229 |